C
Citius Oncology Inc
NASDAQ:CTOR
Citius Oncology Inc
NASDAQ:CTOR
Price:
1.06
USD
-1.85%
Market Closed
Market Cap:
$93.6m
Relative Value
The Relative Value of one CTOR stock under the Base Case scenario is hidden USD. Compared to the current market price of 1.06 USD, Citius Oncology Inc is hidden .
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
CTOR Relative Value
HIDDEN
Multiples Across Competitors
CTOR Competitors Multiples
Citius Oncology Inc Competitors
Citius Oncology Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
C
|
Citius Oncology Inc
NASDAQ:CTOR
|
89.9m USD | 22.8 | -3.8 | -4 | -3.9 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
417.5B USD | 6.8 | 99.9 | 16.3 | 22.6 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
204.7B USD | 5.6 | 26.5 | 15.2 | 15.2 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
184.3B USD | 6.3 | 21.7 | 13.5 | 16.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
121.5B USD | 10.1 | 30.7 | 23.2 | 24.2 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
83.1B USD | 5.8 | 18.5 | 13.9 | 15.9 | |
| AU |
|
CSL Ltd
ASX:CSL
|
69.1B AUD | 3.2 | 35 | 11.5 | 14.5 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 | |
| NL |
|
argenx SE
XBRU:ARGX
|
39.3B EUR | 11.2 | 35.8 | 39 | 39.8 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
